AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Incyte Corporation (INCY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

71.39

0.97 (1.38%)

At close: Feb 18, 2025, 3:59 PM

71.27

-0.17%

After-hours: Feb 18, 2025, 04:42 PM EST

undefined% (undefined)

Bid	70
Market Cap	13.82B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.15
PE Ratio (ttm)	475.93
Forward PE	n/a
Analyst	Hold

Ask	73.58
Volume	981,609
Avg. Volume (20D)	1,898,242
Open	70.86
Previous Close	70.42
Day's Range	70.50 - 71.68
52-Week Range	50.35 - 83.95
Beta	undefined

About INCY

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chr...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 4, 1993

Employees 2,617

Stock Exchange NASDAQ

Ticker Symbol INCY

Website https://www.incyte.com

Full Company Profile

Analyst Forecast

According to 19 analyst ratings, the average rating for INCY stock is "Hold." The 12-month stock price forecast is $77, which is an increase of 7.86% from the latest price.

Buy 36.84%

Hold 57.89%

Sell 5.26%

Stock Forecasts

Next Earnings Release

Incyte Corporation is scheduled to release its earnings on Apr 29, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-2.88%

Incyte shares are trading lower after Citigroup cu... Unlock content with Pro Subscription

1 week ago

-7.86%

Incyte shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS estimate.

News

23 hours ago · businesswire.com

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen 45th Annual Health Care Conference o...

6 days ago · seekingalpha.com

Reevaluating Incyte Corporation After Earnings (Technical Analysis)

Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below it...

1 week ago · seekingalpha.com

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Incyte's Q4 2024 earnings showed mixed results with slight revenue beat but missed non-GAAP earnings estimates. The stock has declined due to 2025 guidance coming below expectations. Despite slowing ...

1 week ago · zacks.com

INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.

1 week ago · seekingalpha.com

Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript

Incyte Corporation (NASDAQ:INCY ) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Ex...

1 week ago · zacks.com

Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stree...

1 week ago · zacks.com

Incyte (INCY) Q4 Earnings Miss Estimates

Incyte (INCY) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.06 per share a year ago.

1 week ago · reuters.com

Incyte reports quarterly sales above estimates on strong demand for key drugs

Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura.

1 week ago · businesswire.com

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones.

1 week ago · businesswire.com

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Load More News